Posted on

ADA 2021: Eli Lilly and Novo Nordisk will continue to compete over GLP-1RA market, says GlobalData

Share

Eli Lilly and Novo Nordisk will continue to compete over the glucagon-like peptide 1 receptor agonist (GLP-1RA) market, with the strong possibility that the two pharmaceutical giants will completely own the space due to the current lack of other marketed competitors, including biosimilars. The two giants will likely push out the remaining competition, namely AstraZeneca’s exenatide franchise, says GlobalData, a leading data and analytics company.
At the 81st Scientific Sessions of the American Diabetes Association (ADA) annual meeting, data was presented on a variety of antidiabetics that fall under the GLP-1RA umbrella, including Eli Lilly’s tirzepatide, Novo …

Read More